1. Home
  2. INBS vs LIXT Comparison

INBS vs LIXT Comparison

Compare INBS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INBS
  • LIXT
  • Stock Information
  • Founded
  • INBS 2016
  • LIXT 2005
  • Country
  • INBS United States
  • LIXT United States
  • Employees
  • INBS N/A
  • LIXT N/A
  • Industry
  • INBS Medical Specialities
  • LIXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • INBS Health Care
  • LIXT Health Care
  • Exchange
  • INBS Nasdaq
  • LIXT Nasdaq
  • Market Cap
  • INBS 6.4M
  • LIXT 5.2M
  • IPO Year
  • INBS N/A
  • LIXT N/A
  • Fundamental
  • Price
  • INBS $1.42
  • LIXT $2.41
  • Analyst Decision
  • INBS
  • LIXT
  • Analyst Count
  • INBS 0
  • LIXT 0
  • Target Price
  • INBS N/A
  • LIXT N/A
  • AVG Volume (30 Days)
  • INBS 71.7K
  • LIXT 15.5K
  • Earning Date
  • INBS 02-07-2025
  • LIXT 11-12-2024
  • Dividend Yield
  • INBS N/A
  • LIXT N/A
  • EPS Growth
  • INBS N/A
  • LIXT N/A
  • EPS
  • INBS N/A
  • LIXT N/A
  • Revenue
  • INBS $3,187,974.00
  • LIXT N/A
  • Revenue This Year
  • INBS $280.88
  • LIXT N/A
  • Revenue Next Year
  • INBS $126.26
  • LIXT N/A
  • P/E Ratio
  • INBS N/A
  • LIXT N/A
  • Revenue Growth
  • INBS 55.29
  • LIXT N/A
  • 52 Week Low
  • INBS $1.00
  • LIXT $1.31
  • 52 Week High
  • INBS $11.70
  • LIXT $4.40
  • Technical
  • Relative Strength Index (RSI)
  • INBS 48.80
  • LIXT 60.86
  • Support Level
  • INBS $1.36
  • LIXT $2.27
  • Resistance Level
  • INBS $1.47
  • LIXT $2.68
  • Average True Range (ATR)
  • INBS 0.08
  • LIXT 0.19
  • MACD
  • INBS 0.01
  • LIXT -0.00
  • Stochastic Oscillator
  • INBS 48.15
  • LIXT 75.71

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: